Tendering process for pneumococcal conjugate vaccine: Difference between revisions
mNo edit summary |
mNo edit summary |
||
| Line 37: | Line 37: | ||
A preliminary answer was to base the selection criteria on the vaccine price and the predicted impact of vaccination on invasive pneumococcal disease in the entire Finnish population. Safety will not be used as one of the criteria because there is no indication about any differences in the safety of the currently licensed pneumococcal vaccine products. | A preliminary answer was to base the selection criteria on the vaccine price and the predicted impact of vaccination on invasive pneumococcal disease in the entire Finnish population. Safety will not be used as one of the criteria because there is no indication about any differences in the safety of the currently licensed pneumococcal vaccine products. | ||
An epidemiological model was applied to assess the differences between the 10- and 13-valent vaccines in quality-adjusted life-years gained and in medical costs saved. If serotype 3 is not included as a vaccine type in the 13-valent vaccine, then the differences between the two vaccines in quality-adjusted life-years gained and in medical costs saved are small in comparison | An epidemiological model was applied to assess the differences between the 10- and 13-valent vaccines in quality-adjusted life-years gained and in medical costs saved. If serotype 3 is not included as a vaccine type in the 13-valent vaccine, then the differences between the two vaccines in quality-adjusted life-years gained and in medical costs saved are small in comparison to differences in predictions due to intrinsic uncertainties in the model. Therefore, the vaccines can be regarded as equally effective and vaccine price should be the predominant selection criterion. | ||
== Rationale == | == Rationale == | ||
Revision as of 16:49, 12 September 2014
| Moderator:Jouni (see all) |
|
|
| Upload data
|
| Main message: |
|---|
| Question:
To answer this question, THL is organising an open discussion during summer and early autumn 2014. The outcome of this process is presented to the National Immunization Technical Advisory Group (NITAG) and the Ministry of Social Affairs and Health in September. The discussion is focussed on three topics:
You can participate in two ways:
You should first browse the pneumococcus assessment pages so that you can give your comments on a right page and check whether your comment has actually been raised already. Comments are not repeated, and irrelevant comments will be removed. All relevant content will stay on the pages. Please note, however, that other participants may try to prove your comments false; if proven false, your comments as such will not be reflected in the final recommendation that is given to NITAG and the Ministry of Social Affairs and Health. |
Question
How should vaccine products be compared in the national procurement of the pneumococcal conjugate vaccine?
Scope
- We restrict the analysis to vaccination within the infant immunisation programme.
- We specify criteria for comparing pneumococcal conjugate vaccine products.
- The aim is to prepare selection criteria that enable the choice of the economically most advantageous tender.
- We discuss assumptions underlying the epidemiological model and the cost-effectiveness analysis.
- The preparation of the criteria is based on current knowledge of the impact of pneumococcal conjugate vaccination.
- The procurement can only involve a product that has marketing authorisation in EU/Finland (see Section 20a of the Medicines Act [1](pdf)).
- The procurement must follow the Act on Public Contracts.
- The discussion on these pages is not binding the preparation of the procurement.
Answer
A preliminary answer was to base the selection criteria on the vaccine price and the predicted impact of vaccination on invasive pneumococcal disease in the entire Finnish population. Safety will not be used as one of the criteria because there is no indication about any differences in the safety of the currently licensed pneumococcal vaccine products.
An epidemiological model was applied to assess the differences between the 10- and 13-valent vaccines in quality-adjusted life-years gained and in medical costs saved. If serotype 3 is not included as a vaccine type in the 13-valent vaccine, then the differences between the two vaccines in quality-adjusted life-years gained and in medical costs saved are small in comparison to differences in predictions due to intrinsic uncertainties in the model. Therefore, the vaccines can be regarded as equally effective and vaccine price should be the predominant selection criterion.
Rationale
The rationale has been summarised in the following three pages: Comparison criteria for pneumococcal vaccines, Epidemiological modelling and Economic evaluation.
Comparison of vaccine products will be based on their price and expected health benefits (Comparison criteria for pneumococcal vaccines). The health benefits mean the expected reduction in the annual number of invasive pneumococcal disease in the Finnish population, if the vaccine would be used in the national infant immunisation programme. The assessment of the benefits is realised by using an epidemiological model. The effectiveness of the vaccination programme will be quantified as the expected improvement in health-associated quality of life. The selection criterion is formulated so that the most cost-effective will be identified (Economic evaluation).
See also